FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer
The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.
CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma
Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.
Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer
Significant progression-free survival was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with maintenance selinexor.
FDA Publishes Final Guidelines for Real-time Review of Oncology Drugs
The FDA finalizes the guidelines of its real-time oncology review to state that submissions must include clinical trial end points that can be “easily interpreted.”
Multiple Myeloma Experts Discuss Treatment Options and New Advances
Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.
CAR T-Cell Therapy Vs Bispecific Antibodies As Multiple Myeloma Treatment
Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.
Communication Prior to Tumor Sequencing Proves Beneficial in Late-Stage Cancer
Researchers advise cancer providers to use online tools, visual aids, and interactive multimedia resources to educate patients before tumor testing.
Black Population Receives Worse Care Vs White Population for CRC Treatment
A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.
Radical Hysterectomies Show Sexual Toxicity in Early-Stage Cervical Cancer
Radical hysterectomies result in worse symptom experience, body image, menopausal symptoms, sexual worry, sex activity and enjoyment compared with simple hysterectomy in those with early-stage cervical cancer.
Maintenance Ibrutinib Improves Efficacy in MCL
The 3-year PFS rate for patients with MCL was 94%, and the OS rate was 97%
Early CT Lung Cancer Screening Significantly Improves Survival in Lung Cancer
Early CT screening leads to a 20-year lung cancer survival rate of 81%.
Lack of Vitamin D may Increase Chemo-Induced Neuropathy Risk in Breast Cancer
Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Avutometinib/Defactinib Shows Efficacy in Treating Low-grade Serous Ovarian Cancer
Results from phase 1 of the RAMP 201 study shows efficacy in treating patients with recurrent low-grade serous ovarian cancer with avutometinib plus defactinib, regardless of previous treatment.
FDA Places Partial Hold on NX-2127 Phase 1 Trial in B-Cell Malignancies
The partial clinical hold on a phase 1 study assessing NX-2127 in those with B-cell malignancies comes after the developer communicated intent to the FDA to move to a different manufacturing process.
THIO/Cemiplimab Shows Significant Disease Control in NSCLC
Results from the phase 2 THIO-101 trial demonstrate disease control in all 19 patients with non–small cell lung cancer who received second-line THIO plus cemiplimab.
Pembrolizumab/177Lu-PSMA-617 May Be a New Treatment for Patients with mCRPC
Results from a phase 1 of study of 177Lu-PSMA-617 in combination with pembrolizumab show significant anti-tumor activity with low toxicity in patients with metastatic castration-resistant prostate cancer.
FDA Classifies 177Lu Vipivotide Tetraxetan Drug Shortage as Resolved
With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer.
Thyroid Cancer Rates Are Higher Among Transgender Female Veterans
Study shows a high prevalence of thyroid cancer in transgender female patients.
Dostarlimab/Chemo Earns Positive CHMP Opinion in Advanced Endometrial Cancer
Data from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial support the use of frontline dostarlimab plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Adjuvant Pembrolizumab Earns European Approval for High-Risk NSCLC
Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.
2 Clarke Drive Cranbury, NJ 08512